Minerva Neurosciences, Inc (NERV): Price and Financial Metrics
GET POWR RATINGS... FREE!
NERV Stock Price Chart Interactive Chart >
NERV Price/Volume Stats
| Current price | $3.34 | 52-week high | $15.27 |
| Prev. close | $3.32 | 52-week low | $2.51 |
| Day low | $3.26 | Volume | 19,300 |
| Day high | $3.43 | Avg. volume | 1,684,263 |
| 50-day MA | $5.87 | Dividend yield | N/A |
| 200-day MA | $5.18 | Market Cap | 17.84M |
Minerva Neurosciences, Inc (NERV) Company Bio
Minerva Neurosciences, Inc. focuses on the development and commercialization of a portfolio of product candidates for the treatment of central nervous system diseases. The company was founded in 2007 and is based in Waltham, Massachusetts.
Latest NERV News From Around the Web
Below are the latest news stories about MINERVA NEUROSCIENCES INC that investors may wish to consider to help them evaluate NERV as an investment opportunity.
Analysts Offer Insights on Healthcare Companies: GlycoMimetics (GLYC) and Minerva Neurosciences (NERV)Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on GlycoMimetics (GLYC – Research Report) and Minerva Neurosciences (NERV – Research Report). GlycoMimetics (GLYC) H.C. Wainwright analyst Edward White maintained a Buy rating on GlycoMimetics today and set a price target of $13.00. The company's shares closed last Wednesday at $0.76, close to its 52-week low of $0.51. According to TipRanks. |
Minerva Neurosciences Reports Third Quarter 2022 Financial Results and Business UpdatesCompany To Host Live Webcast Today at 8:30 a.m. ET Company To Host Live Webcast Today at 8:30 a.m. ET |
Minerva Neurosciences, Inc. (NERV) Q3 2022 Earnings Call TranscriptMinerva Neurosciences, Inc. (NASDAQ:NASDAQ:NERV) Q3 2022 Earnings Conference Call November 9, 2022 08:30 AM ET Company Participants Geoff Race - President Remy Luthringer - CEO Frederick… |
Minerva Neurosciences GAAP EPS of -$1.29 beats by $0.03Minerva Neurosciences press release (NERV): Q3 GAAP EPS of -$1.29 beats by $0.03.Cash, cash equivalents and restricted cash as of September 30, 2022 were approximately $40.3… |
Minerva Neurosciences, Inc: Minerva Neurosciences Reports Third Quarter 2022 Financial Results and Business UpdatesCompany To Host Live Webcast Today at 8:30 a.m. ETBURLINGTON, Mass., Nov. 09, 2022(Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central… |
NERV Price Returns
| 1-mo | 26.04% |
| 3-mo | -65.50% |
| 6-mo | 2.35% |
| 1-year | -57.00% |
| 3-year | -93.32% |
| 5-year | -92.48% |
| YTD | -47.88% |
| 2021 | -65.77% |
| 2020 | -67.09% |
| 2019 | 5.49% |
| 2018 | 11.40% |
| 2017 | -48.51% |
Loading social stream, please wait...